CATALYST BIOSCIENCES, INC.

(CBIO)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
1.770 USD   -1.12%
07/01JDS1, LLC Provides Information to the Shareholders
CI
06/29Catalyst Biosciences Inc Provides Information to Shareholders
CI
06/29Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Catalyst Biosciences Shares Soar After Complement Portfolio Sale

05/23/2022 | 09:54am EDT

By Colin Kellaher


Shares of Catalyst Biosciences Inc. more than doubled in early trading Monday after the biopharmaceutical company said it sold its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Inc. for $60 million in cash.

The South San Francisco, Calif., company in February said it planned to explore options to monetize its assets, and it hired investment bank Perella Weinberg Partners to assist with the process.

Catalyst said it has significantly reduced its cash burn, and that it continues to work with its advisers to evaluate additional moves.

The company said its product candidates now consist of the coagulation-related assets marzeptacog alfa (activated), dalcinonacog alfa and CB 2679d-GT.

Catalyst shares, which closed Friday at 38 cents, were recently changing hands at 92 cents.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

05-23-22 0953ET

Stocks mentioned in the article
ChangeLast1st jan.
CATALYST BIOSCIENCES, INC. -1.12% 1.77 Delayed Quote.95.84%
PERELLA WEINBERG PARTNERS 4.28% 6.09 Delayed Quote.-54.59%
VERTEX PHARMACEUTICALS 0.58% 288.98 Delayed Quote.30.84%
VERTEX, INC. 6.83% 11.73 Delayed Quote.-30.81%
All news about CATALYST BIOSCIENCES, INC.
07/01JDS1, LLC Provides Information to the Shareholders
CI
06/29Catalyst Biosciences Inc Provides Information to Shareholders
CI
06/29Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
AQ
06/27CATALYST BIOSCIENCES : ASSET PURCHASE AGREEMENT - Form 8-K
PU
06/27CATALYST BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21JEC II Associates Engages in Discussions with Catalyst Biosciences
CI
06/17JDS1, LLC Provides Information to the Shareholders
CI
06/09CATALYST BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
05/25Julian D. Singer Solicits Proxies from Shareholders of Catalyst Biosciences
CI
05/24CATALYST BIOSCIENCES : INDEX TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATE..
PU
More news
Analyst Recommendations on CATALYST BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 1,00 M - -
Net income 2022 -30,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,85x
Yield 2022 -
Capitalization 56,3 M 56,3 M -
Capi. / Sales 2022 56,3x
Capi. / Sales 2023 -
Nbr of Employees 45
Free-Float 74,9%
Chart CATALYST BIOSCIENCES, INC.
Duration : Period :
Catalyst Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALYST BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,79
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Nassim Usman President, Chief Executive Officer & Director
Seline E. Miller Chief Financial & Accounting Officer
Augustine J. Lawlor Chairman
Grant Blouse Chief Scientific Officer
Errol B. de Souza Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CATALYST BIOSCIENCES, INC.95.84%56
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-4.30%47 357
BIONTECH SE-38.91%38 276